My watch list
my.bionity.com  
Login  

Hodgkin's lymphoma



Hodgkin's lymphoma
Classification & external resources
Lymph node biopsy showing Hodgkin's lymphoma.
ICD-10 C81.
ICD-9 201
ICD-O: 9650/3-9667/3
DiseasesDB 5973
MedlinePlus 000580
eMedicine med/1022 

Hodgkin's lymphoma, also known as Hodgkin's disease, is a type of lymphoma first described by Thomas Hodgkin in 1832. Hodgkin's lymphoma is characterized clinically by the orderly spread of disease from one lymph node group to another and by the development of systemic symptoms with advanced disease. Pathologically, the disease is characterized by the presence of Reed-Sternberg cells. Hodgkin's lymphoma was one of the first cancers to be cured by radiation. Later it was one of the first to be cured by combination chemotherapy. The cure rate is about 93%, making it one of the most curable forms of cancer.

Additional recommended knowledge

Contents

Epidemiology

Unlike some other lymphomas, whose incidence increases with age, Hodgkin's lymphoma has a bimodal incidence curve; that is, it occurs most frequently in two separate age groups, the first being young adulthood (age 15–35) and the second being in those over 55 years old although these peaks may vary slightly with nationality.[1] Overall, it is more common in men, except for the nodular sclerosis variant (see below), which is more common in women.

The annual incidence of Hodgkin's lymphoma is about 1/25,000 people, and the disease accounts for slightly less than 1% of all cancers worldwide.

The incidence of Hodgkin's lymphoma is increased in patients with HIV infection.[2] In contrast to many other lymphomas associated with HIV infection it occurs most commonly in patients with higher CD4 T cell counts.

Symptoms

Lymph node: Swollen but painless,rubbery lymph nodes are the most common sign of Hodgkin's lymphoma, often occurring in the neck(Cervical and Supraclavicular nodes 80-90% of the times). The lymph nodes of the chest are often affected and these may be noticed on a chest x-ray.

Splenomegaly:occurs in about 30% of people with Hodgkin's lymphoma. The enlargement, however, is seldom massive. Hepatomegally : due to liver involvement in the disease in about 5% of cases. Systemic symptoms :About one-third with Hodgkin's disease may also notice some systemic symptoms, such as low-grade fever, night sweats,10% weight loss, itchy skin (pruritus)-due to increased eosinophils, or fatigue. Classically, involved nodes are painful after alcohol consumption, though this phenomenon is rare. Patients may also present with a cyclic high-grade fever known as Pel-Ebstein fever, although there is debate as to whether or not this truly exists. [3] Systemic symptoms such as fever, night sweats and weight loss are known as B symptoms.

Diagnosis

Hodgkin's lymphoma must be distinguished from non-cancerous causes of lymph node swelling (such as various infections) and from other types of cancer. Definitive diagnosis is by lymph node biopsy (Usually excisional biopsy with microscopic examination). Blood tests are also performed to assess function of major organs and to assess safety for chemotherapy. Positron emission tomography (PET) is used to detect small deposits that do not show on CT scanning. In some cases a Gallium Scan may be used instead of a PET scan.

Pathology

Macroscopy

Affected lymph nodes (most often, laterocervical lymph nodes) are enlarged, but their shape is preserved because the capsule is not invaded. Usually, the cut surface is white-grey and uniform; in some histological subtypes (e.g. nodular sclerosis) a nodular aspect may appear.

Microscopy

Microscopic examination of the lymph node biopsy reveals complete or partial effacement of the lymph node architecture by scattered large malignant cells known as Reed-Sternberg cells (typical and variants) admixed within a reactive cell infiltrate composed of variable proportions of lymphocytes, histiocytes, eosinophils, and plasma cells. The Reed-Sternberg cells are identified as large often bi-nucleated cells with prominent nucleoli and an unusual CD45-, CD30+, CD15+/- immunophenotype. In approximately 50% of cases, the Reed-Sternberg cells are infected by the Epstein-Barr virus.

Characteristics of classic Reed-Sternberg cells include large size (20–50 micrometres), abundant, amphophilic, finely granular/homogeneous cytoplasm; two mirror-image nuclei (owl eyes) each with an eosinophilic nucleolus and a thick nuclear membrane (chromatin is distributed at the cell periphery).

Variants:

  • Hodgkin's cell (atypical mononuclear RSC) is a variant of RS cell, which has the same characteristics, but is mononucleated.
  • Lacunar RSC is large, with a single hyperlobated nucleus, multiple, small nucleoli and eosinophilic cytoplasm which is retracted around the nucleus, creating an empty space ("lacunae").
  • Pleomorphic RSC has multiple irregular nuclei.
  • "Popcorn" RSC (lympho-histiocytic variant) is a small cell, with a very lobulated nucleus, small nucleoli.
  • "Mummy" RSC has a compact nucleus, no nucleolus and basophilic cytoplasm. [4]

Hodgkin's lymphoma can be sub-classified by histological type. The cell histology in Hodgkin's lymphoma is not as important as it is in non-Hodgkin's lymphoma: the treatment and prognosis in Hodgkin's lymphoma depend on the stage of disease rather than the histotype.

Types

Classical

Classical Hodgkin's lymphoma (excluding nodular lymphocyte predominant Hodgkin's) can be subclassified into 4 pathologic subtypes based upon Reed-Sternberg cell morphology and the composition of the reactive cell infiltrate seen in the lymph node biopsy specimen. (M9650/3)

Classic Hodgkin's Lymphoma (CHL) subtypes:

  1. Nodular sclerosing CHL is the most common subtype and is composed of large tumor nodules with lacunar RS cells subtype composed of numerous classic often pleomorphic RS cells with only few reactive lymphocytes which may easily be confused with diffuse large cell lymphoma. (C81.3, M9653/3)
  2. Mixed-cellularity subtype is a common subtype and is composed of numerous classic RS cells admixed with numerous inflammatory cells including lymphocytes, histiocytes, eosinophils, and plasma cells. (C81.2, M9652/3)
  3. Lymphocyte-rich and
  4. lymphocyte depleted are rare subtypes.

Other

Nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL) is no longer classified as a form of classic Hodgkin's lymphoma. This is due to the fact that the RSC variants (popcorn cells) that characterize this form of the disease invariably express B lymphocyte markers such as CD20 (thus making NLPHL an unusual form of B cell lymphoma), and that (unlike classic HL) NLPHL may progress to diffuse large B cell lymphoma. There are small but clear differences in prognosis between the various forms.

Lymphocyte predominant HL is an uncommon subtype composed of vague nodules of numerous reactive lymphocytes admixed with large popcorn-shaped RSC. Unlike classic RSC, the non-classic popcorn-shaped RS cells of NLPHL are CD15 and CD30 negative while positive for the B cell marker CD20. (C81.0, M9659/3)

Staging

After Hodgkin's lymphoma is diagnosed, a patient will be staged: that is, they will undergo a series of tests and procedures which will determine what areas of the body are affected. These procedures will include documentation of their histology, a physical examination, blood tests, chest X-ray radiographs, computed tomography (CT) scans or magnetic resonance imaging (MRI) scans of the chest, abdomen and pelvis, and a bone marrow biopsy. Positron emission tomography (PET) scan is now used instead of the gallium scan for staging. In the past, a lymphangiogram or surgical laparotomy (which involves opening the abdominal cavity and visually inspecting for tumors) were performed. Lymphangiograms or laparotomies are very rarely performed, having been supplanted by improvements in imaging with the CT scan and PET scan.

On the basis of this staging, the patient will be classified according to a staging classification (the Ann Arbor staging classification scheme is a common one):

  • Stage I is involvement of a single lymph node region (I) or single extralymphatic site (Ie);
  • Stage II is involvement of two or more lymph node regions on the same side of the diaphragm (II) or of one lymph node region and a contiguous extralymphatic site (IIe);
  • Stage III is involvement of lymph node regions on both sides of the diaphragm, which may include the spleen (IIIs) and/or limited contiguous extralymphatic organ or site (IIIe, IIIes);
  • Stage IV is disseminated involvement of one or more extralymphatic organs.

The absence of systemic symptoms is signified by adding 'A' to the stage; the presence of systemic symptoms is signified by adding 'B' to the stage.

Prognosis

In 1998, an international effort[5] identified seven prognostic factors that accurately predict the success rate of conventional treatment in patients with locally extensive or advanced stage Hodgkin's lymphoma. Freedom from progression (FFP) at 5 years was directly related to the number of factors present in a patient. The 5-year FFP for patients with zero factors is 84%. Each additional factor lowers the 5-year FFP rate by 7%, such that the 5-year FFP for a patient with 5 or more factors is 42%.

The adverse prognostic factors identified in the international study are:

  • Age >= 45 years
  • Stage IV disease
  • Hemoglobin < 10.5 g/dl
  • Lymphocyte count < 600/µl or < 8%
  • Male
  • Albumin < 4.0 g/dl
  • White blood count >= 15,000/µl

Other studies have reported the following to be the most important adverse prognostic factors: mixed-cellularity or lymphocyte-depleted histologies, male sex, large number of involved nodal sites, advanced stage, age of 40 years or more, the presence of B symptoms, high erythrocyte sedimentation rate, and bulky disease (widening of the mediastinum by more than one third, or the presence of a nodal mass measuring more than 10 cm in any dimension.)

Treatment

See also: ABVD

Patients with early stage disease (IA or IIA) are effectively treated with radiation therapy or chemotherapy. The choice of treatment depends on the age, sex, bulk and the histological subtype of the disease. Patients with later disease (III, IVA, or IVB) are treated with combination chemotherapy alone. Patients of any stage with a large mass in the chest are usually treated with combined chemotherapy and radiation therapy.

Currently, the ABVD chemotherapy regimen is the gold standard for treatment of Hodgkin's disease. The abbreviation stands for the four drugs Adriamycin, bleomycin, vinblastine, and dacarbazine. Developed in Italy in the 1970s, the ABVD treatment typically takes between six and eight months, although longer treatments may be required. Another form of treatment is the newer Stanford V regimen, which is typically only half as long as the ABVD but which involves a more intensive chemotherapy schedule and incorporates radiation therapy. However, in a randomized controlled study, Stanford V was inferior.[6]

Another form of treatment, mainly in Europe for stages > II is BEACOPP. The cure rate with the BEACOPP esc. regimen is approximately 10-15% higher than with standard ABVD in advanced stages. Although this was shown in a landmark paper in The New England Journal of Medicine (Diehl et al.), the US physicians still favor ABVD. Probably because some physicians think that BEACOPP induces more secondary leukemia. However, this seems negligible compared to the higher cure rates. Also, BEACOPP is more expensive because of the G-CSF-support that is required. Currently, the German Hodgkin Study group tests 8x BEACOPP esc vs. 6x BEACOPP esc vs. 8x BEACOPP-14 baseline (HD15-trial).

With appropriate treatment, over 93% of Hodgkin's lymphoma cases are curable to the point of remission.

The high cure rates and long survival of many patients with Hodgkin's lymphoma has led to a high concern with late adverse effects of treatment, including cardiovascular disease and second malignancies such as acute leukemias, lymphomas, and solid tumors within the radiation therapy field. Most patients with early stage disease are now treated with abbreviated chemotherapy and involved-field radiation therapy rather than with radiation therapy alone. Clinical research strategies are exploring reduction of the duration of chemotherapy and dose and volume of radiation therapy in an attempt to reduce late morbidity and mortality of treatment while maintaining high cure rates. Hospitals are also treating those who respond quickly to chemo-therapy with no radiation.

Notable cases

  • The actor Richard Harris died of Hodgkin's lymphoma in 2002 after filming Harry Potter and the Chamber of Secrets as main character Albus Dumbledore.
  • Former NHL star Mario Lemieux was diagnosed with Hodgkin's lymphoma in January 1993. Even after taking 2 months off, Lemieux ended up winning the scoring title that year.
  • Lynden David Hall died of Hodgkin's lymphoma in 2006.
  • Barry Watson, an actor who gained fame in the television series 7th Heaven, had successfully treated Hodgkin's lymphoma.
  • Paul Allen, Microsoft co-founder, was diagnosed and treated for Hodgkin's lymphoma in 1983.
  • Delta Goodrem, Australian singer, was diagnosed with Hodgkin's lymphoma in July 2003.
  • Former head of NBC Entertainment, Brandon Tartikoff, died in 1997 after a 25 year battle with Hodgkin's disease.
  • Senator Arlen Specter (R-PA) was diagnosed with Phase IVB Hodgkin's Disease in 2005, underwent 5 months of chemotherapy, and received a clean bill of health.
  • British actor Roger Tonge who played the disabled Sandy Richardson in the cult British soap opera Crossroads in the 1960s and 1970s died of Hodgkin's Disease in 1981, aged just 35.
  • Alese Coco [2]one of the most notable non-celebrities to have Hodgkin’s lymphoma. Known worldwide to the Hodgkin’s community as a torch bearer for Hodgkin’s research. Died at the age of 23.
  • WWE wrestler Rowdy Roddy Piper.
  • John Millington Synge, the Irish author best known for the play The Playboy of the Western World, died in 1909 from the disease.
  • Dinu Lipatti, the Romanian pianist, died of Hodgkin's disease in 1950, 33 years old.
  • Wayne Shelford, aka 'Buck' Shelford, former All Black rugby player for New Zealand.
  • Elizabeth Madox Roberts, a noted Kentucky poet and novelist, died from Hodgkin's in 1941.
  • Joy Hester, a noted Australian artist, died from Hodgkin's in 1960.

Cultural references

  • A main character in the movie October Sky (and the book Rocket Boys), Miss Riley, was diagnosed with Hodgkin's lymphoma.
  • In the novel Don't Die, My Love, by Lurlene McDaniel, one of the main characters, Luke, is diagnosed with Hodgkin's and dies after about a year and a half.
  • In the latter part of the television series Party of Five, Charlie Salinger (played by Matthew Fox), was diagnosed with Hodgkin's and, through rigorous regimens and treatments, went into remission.
  • In Desperate Housewives, the character of Lynette Scavo, (played by Felicity Huffman) is diagnosed with Hodgkin's lymphoma, which she tries to keep a secret.
  • Bang the Drum Slowly (1974) is a film about a baseball player's last season when only he (Robert DeNiro) and his best friend (Michael Moriarty) know he is dying of Hodgkin's disease.
  • In the television show Curb your Enthusiasm episode "The Five Wood" Larry David believes his friend's father suffered from "the good hodgkin's," and that he learned about it from an episode of Party of Five.
  • In Jeffrey Archer's "Kane and Abel", Matthew Lester is diagnosed with Hodgkin's, but does not disclose his discovery to anyone. His best friend, William Kane, is told by Doctor MacKenzie abut the illness shortly before Matthew's death.
  • In the 1996 film Infinity (with Matthew Broderick and Patricia Arquette), Arline Greenbaum (Arquette) is suspected of having Hodgkin's lymphoma. It later turns out to be lymphatic tuberculosis.
  • Constable Deirdre 'Dash' McKinley in Australian Police Drama Blue Heelers was diagnosed with Hodgkins and shaved her head to save herself the trauma of going through hair loss.

See also

References

  1. ^ Mauch, Peter; James Armitage, Volker Diehl, Richard Hoppe, Laurence Weiss (1999). Hodgkin's Disease. Lippincott Williams & Wilkins, 62-64. ISBN 0-7817-1502-4. 
  2. ^ Biggar RJ, Jaffe ES, Goedert JJ, Chaturvedi A, Pfeiffer R, Engels EA (2006). "Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS". Blood 108 (12): 3786-91. doi:10.1182/blood-2006-05-024109. PMID 16917006.
  3. ^ Asher, Richard (July 6, 1995). "Making Sense". The New England Journal of Medicine 333.
  4. ^ [1]
  5. ^ Hasenclever (1998-11-19). "A Prognostic Score for Advanced Hodgkin's Disease". New England Journal of Medicine 339 (21).
  6. ^ Gobbi PG, Levis A, Chisesi T, et al (2005). "ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi". J. Clin. Oncol. 23 (36): 9198-207. doi:10.1200/JCO.2005.02.907. PMID 16172458.
 
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Hodgkin's_lymphoma". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE